Pharma Company Benefits From Reserved Capacity' Business Model In Strategic CMC Outsourcing Partnership
Source: Almac Group

At Almac, we realize our client partners face a variety of business challenges from changing clinical trial plans to forecasting difficulties particularly for specialized medicines and orphan drug products and as such, we differentiate ourselves by offering the flexibility that clients need.
Working with our client partners, we provide tailored solutions to meet their unique development, manufacturing and packaging outsourcing needs.
This case study is an example of our ‘Reserved Technology Capacity’ business model and provides an overview of:
- The strategic partnership established between Almac and a global Big Pharma company
- How moving from a transactional fee for service model benefited our client partner allowing them to have dedicated capacity on key technology to support their clinical trials
access the Case Study!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online